Heart Failure Oral Therapies at Discharge are Associated with Better Outcome in Acute Heart Failure: A Propensity-Score Matched Study
- 28 August 2017
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 20 (2) , 345-354
Abstract
Aims: Heart failure oral therapies (HFOTs), including beta-blockers (BB), renin–angiotensin system inhibitors (RASi) and mineralocorticoid receptor antagonists, administered before hospital discharge after acute heart failure (AHF) might improve outcome. However, concerns have been raised because early administration of HFOTs may worsen patient's condition. We hypothesized that HFOTs at hospital discharge might be associated with better post-discharge survival. Methods and results: The study population was composed of 19 980 AHF patients from the GREAT registry. The primary and secondary outcomes were 90-day and 1-year all-cause mortality, respectively. Survival was estimated with univariate and covariate-adjusted Cox proportional hazards regression models for the whole population and after propensity-score matching. HFOTs at discharge were consistently associated with no excess mortality in the unadjusted and adjusted analyses of the whole and matched cohorts. In the matched cohort, BB and RASi at discharge were associated with lower 90-day mortality risks compared to the respective untreated groups [hazard ratio (HR) 0.56, 95% confidence interval (CI) 0.46–0.69; and HR 0.53, 95% CI 0.42–0.66, respectively]. The favourable associations of BB and RASi at discharge with 90-day mortality were present in many subgroups including patients with reduced or preserved left ventricular ejection fraction and persisted up to 1 year after discharge. The combination of RASi and BB was associated with an even lower risk of death than RASi or BB alone. Conclusions: Administration of HFOTs at hospital discharge is associated with better survival of AHF patients.Keywords
Funding Information
- Collège de Médecine des Hôpitaux de Paris
- Ministry of Health of the Czech Republic, conceptual development of research organization (65269705)
- Masaryk University (MUNI/A/1362/2015)
- Czech Society of Cardiology
- Instituto de Salud Carlos III (PI15/01019)
- Instituto de Salud Carlos III (PI11/01021)
- Fundació la Marató de TV3 (20152510)
- Catalonia Govern for Consolidated Groups of Investigation (2009/1385)
- Catalonia Govern for Consolidated Groups of Investigation (2014/0313)
- Saudi Heart Association
- the Deanship of Scientific Research at King Saud University, Riyadh, Saudi Arabia (RG -1436-013)
This publication has 33 references indexed in Scilit:
- Association between spironolactone added to beta-blockers and ACE inhibition and survival in heart failure patients with reduced ejection fraction: a propensity score-matched cohort studyEuropean Journal of Clinical Pharmacology, 2013
- Association of Spironolactone Use With All-Cause Mortality in Heart FailureCirculation: Heart Failure, 2013
- Association Between Elevated Blood Glucose and Outcome in Acute Heart FailureJACC, 2013
- Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or PneumoniaJAMA, 2013
- Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial*Critical Care Medicine, 2011
- Eplerenone in Patients with Systolic Heart Failure and Mild SymptomsNew England Journal of Medicine, 2011
- Trends in Length of Stay and Short-term Outcomes Among Medicare Patients Hospitalized for Heart Failure, 1993-2006JAMA, 2010
- B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episodeEuropean Heart Journal, 2009
- The perindopril in elderly people with chronic heart failure (PEP-CHF) studyEuropean Heart Journal, 2006
- The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart FailureNew England Journal of Medicine, 1999